Ars Pharmaceuticals earnings were -$49.1M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest SPRY earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$19.1M, up 52.8% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, SPRY reported annual earnings of -$54.4M, with 56.8% growth. The next SPRY earnings date is Mar 19, 2025.
Ars Pharmaceuticals Earnings Reports & History FAQ
What were Ars Pharmaceuticals's earnings last quarter?
On SPRY's earnings call on Invalid Date, Ars Pharmaceuticals (NASDAQ: SPRY) reported Q3 2024 earnings per share (EPS) of -$0.20, up 25% year over year. Total SPRY earnings for the quarter were -$19.13 million. In the same quarter last year, Ars Pharmaceuticals's earnings per share (EPS) was -$0.16.
The next SPRY earnings call is Invalid Date. Add SPRY to your watchlist to be reminded of Ars Pharmaceuticals's next earnings date.
What was SPRY's earnings growth in the past year?
As of Ars Pharmaceuticals's earnings date in Invalid Date, Ars Pharmaceuticals's earnings has grown year over year. SPRY earnings in the past year totalled -$49.10 million.
Is Ars Pharmaceuticals profitable or losing money?
As of the last Ars Pharmaceuticals earnings report, Ars Pharmaceuticals is currently losing money. Ars Pharmaceuticals's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$49.10 million, a 20.32% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.